HUP9900011A2 - A GAX protein alkalmazása rák kezelésére - Google Patents

A GAX protein alkalmazása rák kezelésére

Info

Publication number
HUP9900011A2
HUP9900011A2 HU9900011A HUP9900011A HUP9900011A2 HU P9900011 A2 HUP9900011 A2 HU P9900011A2 HU 9900011 A HU9900011 A HU 9900011A HU P9900011 A HUP9900011 A HU P9900011A HU P9900011 A2 HUP9900011 A2 HU P9900011A2
Authority
HU
Hungary
Prior art keywords
subject
treatment
treating cancer
cancers
variant
Prior art date
Application number
HU9900011A
Other languages
English (en)
Inventor
Didier Branellec
Patrice Denefle
Aude Leroux
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9900011A2 publication Critical patent/HUP9900011A2/hu
Publication of HUP9900011A3 publication Critical patent/HUP9900011A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya a GAX prőteint vagy variánsát, vagy ezek egy részétkódőló nűkleinsav terápiás alkalmazása példáűl rákők kezelésére. A találmány tárgya a GAX prőteint vagy variánsát, vagy ezek egy részétkódőló nűkleinsav terápiás alkalmazása rákők kezelésére, pőntősabbanrákőknak egy őnkőgént, példáűl a műtáns ras-t kifejező, vagy egy tűmőrszűppresszőr génben, példáűl a p53-ban hiányős tűmőrős sejtekben aszabályőzőttságát elvesztett sejtősztódás gátlásával történőkezelésére szőlgáló eljárás. A találmány tárgyát képezi ennekszabályőzását lehetővé tevő génterápiás vektőrők alkalmazása, valamintaz ezeket tartalmazó gyógyszerkészítmények. ŕ
HU9900011A 1995-10-31 1996-10-28 Use of protein gax for treating cancer HUP9900011A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512871A FR2740344B1 (fr) 1995-10-31 1995-10-31 Application de la proteine gax au traitement de cancers

Publications (2)

Publication Number Publication Date
HUP9900011A2 true HUP9900011A2 (hu) 1999-04-28
HUP9900011A3 HUP9900011A3 (en) 1999-11-29

Family

ID=9484112

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900011A HUP9900011A3 (en) 1995-10-31 1996-10-28 Use of protein gax for treating cancer

Country Status (13)

Country Link
EP (1) EP0858466A1 (hu)
JP (1) JPH11514881A (hu)
KR (1) KR19990067174A (hu)
AU (1) AU730324B2 (hu)
BR (1) BR9611206A (hu)
CA (1) CA2233250A1 (hu)
CZ (1) CZ131598A3 (hu)
FR (1) FR2740344B1 (hu)
HU (1) HUP9900011A3 (hu)
NO (1) NO981822L (hu)
SK (1) SK56198A3 (hu)
WO (1) WO1997016459A1 (hu)
ZA (1) ZA969147B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
WO2002000241A2 (en) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
WO2009088256A2 (ko) 2008-01-09 2009-07-16 Konkuk University Industrial Cooperation Corp 배큘로바이러스-기반 백신
KR101230913B1 (ko) 2009-11-06 2013-02-07 중앙대학교 산학협력단 나노입자-기반된 유전자 운반체
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
US9404090B2 (en) 2011-11-24 2016-08-02 Viromed Co., Ltd. Adenovirus producing novel cell line and the use thereof
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
CN108289920A (zh) 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
CN111630159A (zh) 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose

Also Published As

Publication number Publication date
FR2740344B1 (fr) 1997-11-21
AU7498296A (en) 1997-05-22
WO1997016459A1 (fr) 1997-05-09
NO981822D0 (no) 1998-04-23
KR19990067174A (ko) 1999-08-16
EP0858466A1 (fr) 1998-08-19
ZA969147B (en) 1997-05-27
HUP9900011A3 (en) 1999-11-29
SK56198A3 (en) 1998-11-04
AU730324B2 (en) 2001-03-01
CZ131598A3 (cs) 1998-08-12
BR9611206A (pt) 1999-03-30
JPH11514881A (ja) 1999-12-21
NO981822L (no) 1998-04-23
CA2233250A1 (fr) 1997-05-09
FR2740344A1 (fr) 1997-04-30

Similar Documents

Publication Publication Date Title
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
ATE242324T1 (de) Menschliche kalziumkanale und verwendungen davon
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
SE8900247L (sv) Ett nytt bifunktionellt tillvaextmodulerande glykoprotein
DK0839154T3 (da) Biologiske aktive peptider og præparater samt anvendelse deraf
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DK85786D0 (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
DE69422726T2 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE223912T1 (de) Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
NO993943L (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DK0689586T3 (da) VPR-funktion og -aktivitet
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.